Triple combination superior to double combination.

Area of Science:

• HIV/AIDS Research
• Antiretroviral Therapy
• Immunology

Background:

• Antiretroviral therapy is crucial for managing HIV infection.
• Evaluating novel drug combinations is essential for improving treatment outcomes.
• Nevirapine is an investigational nonnucleoside reverse transcriptase inhibitor.

Purpose of the Study:

• To compare the efficacy of a triple combination therapy (AZT, ddI, nevirapine) versus a double combination therapy (AZT, ddI) in HIV patients.
• To assess the impact of these regimens on surrogate markers such as T-cell counts and viral load.
• To explore potential differences in clinical endpoints between the treatment groups.

Main Methods:

• A study involving 241 patients within the AIDS Clinical Trials Group (ACTG).
• Comparison of treatment outcomes between patients receiving triple therapy (AZT, ddI, nevirapine) and double therapy (AZT, ddI).
• Monitoring of surrogate markers including T-cell counts and viral load over a 40-week period.

Main Results:

• The triple combination therapy demonstrated a 40% increase in T-cells over baseline, sustained for 40 weeks.
• Greater reductions in viral load were observed in the triple combination group.
• No significant difference in clinical endpoints was noted, except for a trend towards fewer events in the triple combination group, particularly in patients with low baseline T-cell counts (<50).

Conclusions:

• Triple combination therapy with AZT, ddI, and nevirapine shows superior surrogate marker response compared to dual therapy.
• Nevirapine-containing regimens may offer benefits in managing HIV, particularly in specific patient subgroups.
• Further research into clinical endpoints is warranted for nevirapine-based treatment strategies.